氘代芦可替尼(Deuruxolitinib Phosphate) - 药物靶点：JAK1 x JAK2_在研适应症：斑秃_专利_临床

概要

基本信息

药物类型

小分子化药

别名

D8-ruxolitinib、Deuruxolitinib、deuruxolitinib

+ [7]

靶点

JAK1 x JAK2

作用方式

抑制剂

作用机制

JAK1抑制剂(酪氨酸蛋白激酶JAK1抑制剂)、JAK2抑制剂(酪氨酸蛋白激酶JAK2抑制剂)

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病

在研适应症

斑秃

非在研适应症-

原研机构

Concert Pharmaceuticals, Inc.

在研机构

Concert Pharmaceuticals, Inc.

Incyte Corp.

Sun Pharmaceutical Industries Ltd.

+ [1]

非在研机构-

权益机构

Concert Pharmaceuticals, Inc.

Sun Pharmaceutical Industries Ltd.

最高研发阶段批准上市

首次获批日期

美国 (2024-07-25),

斑秃

最高研发阶段(中国)-

特殊审评快速通道 (美国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

分子式C17H18N6

InChIKeyHFNKQEVNSGCOJV-FBXGHSCESA-N

CAS号1513883-39-0

关联

19

项与氘代芦可替尼相关的临床试验

NCT05478772

/ Completed临床1期

A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study to Evaluate the Effect of Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

A single center, Phase 1, open-label, fixed-sequence, drug-drug interaction study to evaluate the effect of multiple doses of Fluconazole, a CYP3A4 and CYP2C9 inhibitor, on the pharmacokinetics (PK) of CTP-543 in healthy subjects

开始日期2022-07-11

申办/合作机构

Concert Pharmaceuticals, Inc.

NCT05467709

/ Completed临床1期

A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects

This is a single center, Phase 1, open-label, fixed-sequence, drug-drug interaction study to determine the effect of CTP-543 on the pharmacokinetics (PK) of midazolam in healthy adult subjects

开始日期2022-06-21

申办/合作机构

Concert Pharmaceuticals, Inc.

NCT05467696

/ Completed临床1期

A Phase 1 Open-Label, Two-Period, Two-Treatment, Crossover Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers

This is an open-label, single-dose, two period crossover study to evaluate the effect of food on the bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers

开始日期2022-06-14

申办/合作机构

Concert Pharmaceuticals, Inc.

100 项与氘代芦可替尼相关的临床结果

登录后查看更多信息

100 项与氘代芦可替尼相关的转化医学

登录后查看更多信息

100 项与氘代芦可替尼相关的专利（医药）

登录后查看更多信息

19

项与氘代芦可替尼相关的文献（医药）

2025-06-01·PHARMACOLOGICAL RESEARCH

Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update

Review

作者: Roskoski, Robert

Because of the deregulation of protein kinase action in many inflammatory diseases and cancer, the protein kinase family has become one of the most significant drug targets in the 21st century. There are 85 FDA-approved protein kinase antagonists that target about two dozen different enzymes and four of these drugs were approved in 2024 and a fifth was approved in 2025. Of these drugs, five target dual specificity protein kinases (MEK1/2), fourteen inhibit protein-serine/threonine protein kinases, twenty-one block nonreceptor protein-tyrosine kinases, and 45 target receptor protein-tyrosine kinases. The data indicate that 75 of these drugs are prescribed for the treatment of neoplasms. Seven drugs (abrocitinib, baricitinib, deucravacitinib, deuruxolitinib, ritlecitinib, tofacitinib, upadacitinib) are prescribed for the management of inflammatory diseases (atopic dermatitis, rheumatoid arthritis, psoriasis, alopecia areata, and ulcerative colitis). Of the 85 FDA-approved agents, about two dozen are used in the treatment of multiple diseases. The following four drugs received FDA approval in 2024 - deuruxolitinib (alopecia areata), ensartinib and lazertinib (non-small cell lung cancer), and tovorafenib (pediatric glioma) while mirdametinib was approved in 2025 for the treatment of type I neurofibromatosis (von Recklinghausen disease). Apart from netarsudil, temsirolimus, and trilaciclib, the approved protein kinase blockers are orally bioavailable. This article summarizes the physicochemical properties of all 85 FDA-approved small molecule protein kinase inhibitors including the molecular weight, number of hydrogen bond donors/acceptors, ligand efficiency, lipophilic efficiency, polar surface area, and solubility. A total of 39 of the 85 FDA-approved drugs have a least one Lipinski rule of 5 violation.

2025-06-01·JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Most men choose eyebrows versus scalp hair: Response to Mostaghimi et al., “Evaluation of eyebrow and eyelash regrowth and patient satisfaction in the phase 3 THRIVE-AA2 trial of deuruxolitinib in adult patients with alopecia areata”

Letter

作者: Coppinger, Austin J ; Wambier, Carlos G

2025-04-01·Journal of Cosmetic Dermatology

The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study

Review

作者: Bamimore, Mary A. ; Mirmirani, Paradi ; Piguet, Vincent ; Talukder, Mesbah ; Gupta, Aditya K.

ABSTRACT:

Background:

Scant evidence exists for the relative efficacy of therapies for alopecia areata (AA)—including those approved by the Food and Drug Administration, namely, baricitinib, deuruxolitinib, and ritlecitinib.

Aims:

We determined the relative efficacy and safety of monotherapy with janus kinase inhibitors (JAKIs), apremilast, and dupilumab.

Methods:

Following a systematic review, we conducted Bayesian network meta‐analysis (NMAs) that produced Surface Under the Cumulative RAnking (SUCRA) values and point estimates for pairwise relative effects; we also performed sensitivity analyses.

Results:

In total, regimens with eight various JAKIs were compared, namely, ruxolitinib, ATI‐501, baricitinib, brepocitinib, deuruxolitinib, ivarmacitinib, ritlecitinib, and tofacitinib. Our analyses ranked “deuruxolitinib 12 mg twice daily for 24 weeks,” the most efficacious insofar as “proportion of participants achieving SALT ≤ 20 at 24 weeks” (SALT20) (SUCRA = 92.6%), and “proportion of participants achieving SALT ≤ 10 at 24 weeks” (SALT10) (SUCRA = 97.7%). As per SALT20, the highest‐ranked regimen was more efficacious than “baricitinib 2 mg once daily for 24 weeks” (odds ratio [OR] = 5.37, 95% credible interval [CI] = 1.59, 13.70, p < 0.05). Furthermore, the efficacy of the FDA‐approved JAKIs exhibited a dose‐dependent relationship; for instance, baricitinib 4 mg once daily for 24 weeks was more efficacious than “baricitinib 2 mg once daily for 24 weeks” in terms of SALT20 (OR = 2.25, 95% CI = 1.56, 3.21, p < 0.05). Results from our sensitivity analyses support that our base analyses were robust.

Conclusions:

We produced high‐quality evidence on the comparative effectiveness of monotherapies for AA with various regimens of 8 JAKIs, including the FDA‐approved ones. Our findings can improve clinicians' decision‐making and update guidelines for medical practice.

127

项与氘代芦可替尼相关的新闻（医药）

2025-05-23

·ETPharma

Sun Pharma Q4 revenue nears ₹13000 cr, weak US sales drags down Q4 net profit

Mumbai: Indian pharma major Sun Pharma Q4 FY2024-25 total revenue from operation reported an year-on-year (YoY) increase of 8 per cent to ₹12,958 crore, up from ₹11,982 crore of the previous fiscal. The net profit for the period stood at ₹2,153 crore, reflecting sharp YoY contraction of 19 per cent against the corresponding quarter profit of ₹2,658 crore. At a margin of 28.7 per cent the drugmaker's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) went up 22.4 per cent to ₹3,716 crore. While its formulation sales in India, Emerging markets and Rest of the world reported an expansion, the US formulation sales reported a YoY decline of 2.5 per cent to $464 million or around ₹4000 crore For the full financial year, the country’s largest drugmaker total revenue increased by 8.5 per cent to ₹52,578 crore, and the net profit expanded by 14 per cent to ₹10,920 crore. In the 12-month period the company India and US formulations business —whch accounts the maximum share of its total sales—clocked ₹16,923 crore (up 13.7 per cent YoY) and $1921 million or around ₹16,330 crore (up by 3.6 per cent from the previous cycle). The company's complete fiscal R&D expenditure stood at ₹3,248 crore (around 6.2 per cent of the total sales) and of which ₹816 crore was invested in the lat quarter. Global Specialty sales for the fiscal crossed $1 billion, increasing by 17.1 per cent to $ 1,216 million (around ₹10,321 crore). “Our robust performance is driven by improving market share in India and growth in Global Specialty and we look forward to Specialty becoming an increasingly important part of our business,” said Dilip Shanghvi, Chairman and Managing Director, Sun Pharma. Under its speciality portfolio, the company’s key differentiator from its Indian peers , Sun Pharma is planning to launch Leqselvi—a therapy for severe alopecia areata (a type of hair loss) and Unloxcyt—a metastatic cutaneous squamous cell carcinoma drug , in the US market. “The nearterm pipeline in Global Specialty is promising, with products such as Leqselvi and Unloxcyt—the latter through our recently announced Checkpoint acquisition—offering significant improvements in patient care,” Shanghvi, noted. Besides this the company is expecting topline results of its psoriatic late-stage candidate and is looking to secure regulators approval of its soft tissue sarcoma therapy ‘Fibromun’. Following the announcement of results, the board has proposed a final dividend of ₹ 5.5 per share. This is in addition to the interim dividend of ₹10.5 per share paid earlier during the fiscal , taking the total dividend for FY25 to ₹16 per share. By Online Bureau ,

并购财报

2025-05-22

·药事纵横

太阳制药公布2024-2025财年业绩，净利润上涨19%

2025年5月22日，印度最大制药企业太阳制药（Sun Pharmaceutical Industries Limited）公布了2024-2025财年（截至2025年3月31日）的业绩报告。尽管四季度美国市营收小幅下滑，但公司全年仍实现总营收5204.1亿卢比（约合62.6亿美元*），同比增长9.0%；调整后净利润达1198.4亿卢比（约合14.4亿美元），同比增长19.0%。董事会宣布每股16卢比的年度总股息，较上年提升18.5%。这份成绩单的背后，是印度本土市场的强势增长与全球专科药物（Global Specialty）业务的加速扩张。一、核心财务数据：专科业务贡献近20%收入，利润率持续提升1. 季度表现Q4FY25总收入：1281.6亿卢比（约合15.4亿美元），同比增长8.5%EBITDA利润率：28.7%（同比提升3.3个百分点），主要受益于高毛利专科药物占比提升及成本优化。净利润分化：调整后净利润增长4.8%至288.9亿卢比，但报告净利润同比下降19.0%，主因Q4FY24包含一次性收益。2. 全年亮点区域收入结构：印度市场：销售额1692.3亿卢比（占比32.5%），同比增长13.7%，增速领跑所有市场。美国市场：销售额19.2亿美元（占比31.4%），增速放缓至3.6%，Q4同比下滑2.5%受仿制药价格竞争拖累。全球专科药物：销售额12.2亿美元（占比19.7%），同比增长17.1%，成为第二大收入来源。研发投入：全年研发支出324.8亿卢比（占收入6.2%），重点投向专科药物管线。二、业绩驱动因素解析1. 印度市场：处方龙头地位巩固，市占率提升至8.3%处方主导型增长：根据AIOCD AWACS数据，太阳制药在印度2590亿卢比的医药市场中市占率从8.0%提升至8.3%，排名第一。SMSRC报告显示，公司在13个医生类别中的处方量领先。产品策略：全年推出10款新产品，覆盖慢性病和专科领域，推动印度Q4销售增长13.6%。2. 全球专科药物：创新管线进入收获期核心产品贡献：皮肤病药物Ilumya和眼科产品持续放量，专科业务收入占比从FY24的18%提升至19.7%。管线里程碑：Leqselvi：（重度斑秃治疗药）和Unloxcyt（皮肤鳞状细胞癌治疗药）将于FY26在美国上市，后者通过收购Checkpoint Therapeutics获得。NidlegyTM（皮肤癌治疗药）已向欧洲药监局（EMA）提交上市申请。研发进展：8款创新药处于临床阶段，其中Fibromun（软组织肉瘤）和SCD-044（特应性皮炎）预计2025年公布关键数据。3. 美国市场：仿制药承压，专科药物补位仿制药挑战：Q4美国仿制药销售额下滑2.5%，反映行业价格压力。但全年仍增长3.6%，得益于542款已获批ANDA（仿制药申请）的稳定供应。专科药物对冲风险：专科业务在美国增长8.6%，部分抵消仿制药下滑影响。4. 新兴市场与API业务：稳健增长新兴市场：全年销售11.1亿美元（+7.0%），俄罗斯、巴西等地区需求强劲。原料药（API）：外部销售额增长11%至212.9亿卢比，支持公司制剂业务垂直整合优势。三、管理层战略与未来展望董事长Dilip Shanghvi在财报中强调：“专科药物将成为公司未来增长的核心引擎。”公司计划通过以下举措维持增长动能：加速专科药物商业化：Leqselvi和Unloxcyt的上市将进一步提升专科业务占比至20%以上。印度市场深耕：扩大基层医疗覆盖，利用数字化营销巩固处方领导地位。研发管线优化：聚焦肿瘤、皮肤病和代谢疾病领域，推动5款创新药在2026年前进入III期临床。四、风险提示美国仿制药竞争：若专科药物放量不及预期，美国市场增速可能进一步放缓。并购整合风险：Checkpoint Therapeutics的收购需通过监管审批，Unloxcyt上市存在不确定性。结语太阳制药FY25业绩印证了其“本土+专科”双引擎战略的有效性。随着创新管线逐步兑现，公司正从传统仿制药企向专科药龙头转型。投资者可关注2025年下半年Ilumya的III期数据及专科药物上市进度，这些将成为下一阶段股价的关键催化剂。（注：汇率按年报披露Q4平均汇率1美元=86.62卢比换算）药事纵横投稿须知：稿费已上调，欢迎投稿

2025-05-19

·药融圈

当仿制药巨头学会“钞能力”，用钱砸出全球霸权：买新药

▲8月1-2日 2025生物医药创新博览会扫码报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。此前在2025年3月，印度太阳制药（Sun Pharma）和Checkpoint Therapeutics签订了一份合并协议，根据协议，Checkpoint继续作为交易的存续公司及太阳制药的全资子公司，以股票代码CKPT继续在纳斯达克交易。合并的总交易价值高达约4.16亿美元，这笔交易预计会在2025年第二季度完成。免疫疗法创新矩阵的“破壁者”从摩熵医药数据库获悉，Checkpoint是Fortress的控股子公司，2014年11月在特拉华州注册成立，作为一家商业阶段的免疫疗法和靶向肿瘤学公司，主要专注于实体瘤癌症患者的新型疗法的收购、开发和商业化。药融云数据，www.pharnexcloud.com；改名后为摩熵医药数据2024年12月13日，Checkpoint的UNLOXCYT（cosibelimab-ipdl）获批用于治疗不适合根治性手术或根治性放疗的转移性皮肤鳞状细胞癌（CSCC）或局部晚期CSCC成人患者，这是第一个也是唯一一个获批上市的PD-L1阻断抗体。作为Checkpoint的明星产品，UNLOXCYT具有独特的“免疫检查点阻断+ADCC杀伤”双重机制。通过阻断PD-L1的免疫抑制作用，重新激活机体免疫系统对肿瘤细胞的攻击，同时利用ADCC功能直接杀伤肿瘤细胞。处于临床阶段的在研产品还有Olafertinib，这是一种第三代表皮生长因子受体（EGFR）抑制剂，是布局非小细胞肺癌治疗领域的重要在研产品。现有的EGFR抑制剂在治疗过程中面临耐药等问题，olafertinib旨在克服这些难题，为EGFR突变阳性非小细胞肺癌患者提供新的治疗方案。目前，该产品处于评估阶段，公司通过一系列临床试验，从安全性、有效性等多方面对其进行深入研究，探索最佳的用药剂量、治疗周期以及联合治疗方案等，期望其能在非小细胞肺癌治疗市场中占据一席之地。其他临床前开发阶段的候选产品还有CK-103（BET抑制剂）、CK-302（抗GITR单克隆抗体）和CK-303（抗CAIX抗体）。2024年度，Checkpoint的研发费用为3620万美元，与2023年度的4360万美元相比减少了740万美元。一般和行政费用为2010万美元，2023年度为870万美元，与之相比增加了1140万美元。归属于普通股股东的净亏损为5620万美元，或每股1.42美元，而2023年度净亏损为5180万美元，或每股3.17美元。截止2024年12月31日，Checkpoint的现金及现金等价物总额为660万美元。从“仿制药巨头”到“创新药先锋”的转型通过收购Checkpoint，太阳制药得以进入PD-L1免疫治疗市场，进一步完善了其在肿瘤治疗领域的布局；另外，太阳制药作为印度最大的制药商，在美国、欧洲、日本等全球主要医药市场都拥有广泛的业务布局和销售网络，近年来公司一直致力于从仿制药向创新药转型，并在全球范围内积极拓展业务，收购Checkpoint是其在创新药领域迈出的重要一步。2023年3月，太阳制药以5.76亿美元的价格完成了对Concert Pharmaceuticals的收购，此次收购不仅将Concert的氘代新药Deuruxolitinib（一种选择性JAK1/2抑制剂）添加到其皮肤病学产品组合中，还扩大了其在波士顿生物技术中心的影响力。2024年7月，FDA批准Deuruxolitinib（商品名LEQSELVI）用于治疗成人严重斑秃。关于太阳制药太阳制药成立于1983年，经历起步阶段后，1997年完成了首次国际收购，以750万美元收购美国底特律的Caraco药厂；2000年之后，公司加快了并购步伐，先后收购了Pradeep Drug Company、Phlox Pharma等多个企业，成为全球第四大仿制药企业；2010年之后，公司发展战略调整，大幅增加品牌药管线建设力度，重点布局眼科和皮肤科等专业药领域；2014年，太阳制药以40亿美元收购印度仿制药巨头Ranbaxy Laboratories，成为印度最大药厂和全球第五大特种仿制药公司，此后公司继续通过收购、合作等方式不断拓展业务。近两年除了上述提到的收购外，2024年还完成了对Taro Pharma（2010年收购多数股权，2024年完成全资收购）的收购，与Philogen S.p.A. 就Fibromun（一种创新的抗癌免疫疗法）达成了全球许可协议。如今的太阳制药是印度最大的制药公司，市场份额约为8.5%，在包括精神病学、神经学、心脏病学、骨科、胃肠病学、肾脏学、糖尿病学、皮肤科等多个治疗领域占据领先地位；同时在印度拥有35个品牌位列印度前300大医药品牌之中，其中前10大品牌贡献了印度收入的约18%；2024财年（2023.04~2024.03）总销售额为4775.85亿卢比（56.03亿美元），同比增长10.4%，2025财年前三季度总销售额为3922.57亿卢比（46.01亿美元），与上年同期相比增长9.1%。参考：NMPA/CDE；摩熵医药数据库，https://pharma.bcpmdata.com/；FDA/EMA/PMDA；相关公司公开披露（除标注外，正文图片均来自企业官网）；https://sunpharma.com/；https://sunpharma.com/investors/；https://sunpharma.com/media/?q=/%20media&/#press-releases；https://checkpointtx.com/；https://checkpointtx.com/pipeline/；https://ir.checkpointtx.com/；等等。会议推荐 | 点击查看详情植根上海、辐射全球,药融圈作为生物医药产业级战略平台,以"让智慧与人脉无界流动"为使命,构建覆盖药物研发、生产、流通、商业化的全产业链赋能体系。通过智能化云服务、精准资源链接、产业智库与生态社群四大核心引擎,打造中国医药价值流动的基础设施。在全球化与数字化双重浪潮下,药融圈正重新定义医药资源的流通范式--这里不仅是信息与人脉的枢纽站,更是催生产业变革的化学反应器。我们以中国为原点,编织全球医药智慧网络,让每一次精准链接都成为企业跨越式增长的催化剂。点点赞点分享点推荐

并购免疫疗法抗体药物偶联物财报申请上市

100 项与氘代芦可替尼相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
斑秃	美国	Sun Pharmaceutical Industries, Inc.	2024-07-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04797650 \| NCT04518995 (AA-2, FDA_CDER) 人工标引	临床3期	斑秃	1,209	Placebo twice daily (Trial AA-1)	遞網築鑰選繭憲觸範壓(簾獵廠鬱憲醖艱醖餘壓) = 築鬱範繭糧壓繭膚願獵衊襯淵齋鹽鹽製淵製簾 (廠鏇衊積獵膚襯鑰窪蓋 ) 更多	积极	2024-07-25
				LEQSELVI 8 mg twice daily (Trial AA-1)	遞網築鑰選繭憲觸範壓(簾獵廠鬱憲醖艱醖餘壓) = 選簾構窪網艱構襯積鏇衊襯淵齋鹽鹽製淵製簾 (廠鏇衊積獵膚襯鑰窪蓋 ) 更多
NCT04797650 (THRIVE-AA2, EADV2023)	临床3期	斑秃	517	Deuruxolitinib 8 mg BID	艱衊獵夢構窪夢鬱獵憲(艱觸襯淵餘窪膚鑰觸網) = 膚簾鬱願餘簾衊壓衊願衊鹽獵積鹽鑰範網憲構 (鬱糧夢鏇艱鬱選獵觸鏇 )	积极	2023-10-11
				Deuruxolitinib 12 mg BID	艱衊獵夢構窪夢鬱獵憲(艱觸襯淵餘窪膚鑰觸網) = 遞憲繭夢構遞顧壓製膚衊鹽獵積鹽鑰範網憲構 (鬱糧夢鏇艱鬱選獵觸鏇 )
NCT04797650 (AA-2 \| THRIVE-AA2, CTgov)	临床3期	斑秃	517	CTP-543 matching placebo (Placebo)	製繭遞鹽願窪鹽簾顧壓 = 窪淵鹽廠範膚鹽夢獵衊醖糧憲鹽願築簾顧餘壓 (鹹鹹鏇艱選壓蓋襯廠鏇, 積鬱築範膚鬱醖糧齋網 ~ 鑰網積選繭鹽醖願襯艱) 更多	-	2023-07-03
				CTP-543 (CTP-543 8 mg BID)	製繭遞鹽願窪鹽簾顧壓 = 製鹽觸夢鬱鹹簾遞獵願醖糧憲鹽願築簾顧餘壓 (鹹鹹鏇艱選壓蓋襯廠鏇, 鏇鹽願襯鬱糧糧構憲鑰 ~ 淵餘構齋選築淵窪遞選) 更多
NCT04518995 (AA-1 \| THRIVE-AA1, CTgov)	临床3期	斑秃	706	CTP-543 matching placebo (Placebo)	醖繭繭積艱簾遞選齋餘 = 衊鏇襯壓齋網簾壓壓襯構顧餘鑰顧繭積積鏇顧 (製鹹鑰築窪築築窪窪艱, 蓋積範廠製鏇鹹選糧餘 ~ 觸衊淵網齋網願繭鑰顧) 更多	-	2023-05-03
				CTP-543 (CTP-543 8 mg BID)	醖繭繭積艱簾遞選齋餘 = 選構遞築顧壓選艱膚壓構顧餘鑰顧繭積積鏇顧 (製鹹鑰築窪築築窪窪艱, 鑰膚簾網選壓顧餘糧艱 ~ 遞醖願蓋鑰構廠糧鏇獵) 更多
NCT03941548 (CTgov)	临床2期	斑秃	66	CTP-543 Matching Placebo+CTP-543 (CTP-543 12 mg BID)	淵簾繭憲範醖餘齋壓糧(範鑰憲網網糧襯顧窪餘) = 襯餘鑰襯醖築淵簾選淵鏇窪積獵壓壓膚製鏇蓋 (餘簾齋艱鹹蓋製憲繭餘, 34.747) 更多	-	2023-04-05
				CTP-543 Matching Placebo+CTP-543 (CTP-543 24 mg QD)	淵簾繭憲範醖餘齋壓糧(範鑰憲網網糧襯顧窪餘) = 齋製網鹽製獵積鑰製壓鏇窪積獵壓壓膚製鏇蓋 (餘簾齋艱鹹蓋製憲繭餘, 37.887) 更多
NCT04518995 (THRIVE-AA1, AAD2023)	临床3期	斑秃	706	Placebo	餘顧製選簾衊積顧糧蓋(顧齋餘願獵淵廠艱糧夢) = 醖構膚範選膚範鏇網構鑰襯簾構獵糧淵觸醖獵 (膚淵憲選築齋鏇醖憲觸 )	-	2023-03-17
				CTP-543 8 mg BID	餘顧製選簾衊積顧糧蓋(顧齋餘願獵淵廠艱糧夢) = 襯夢襯繭構衊鏇遞願衊鑰襯簾構獵糧淵觸醖獵 (膚淵憲選築齋鏇醖憲觸 )
NCT03811912 (CTgov)	临床2期	斑秃	57	CTP-543 (CTP-543 8 mg BID)	衊鬱積衊簾範夢廠鬱壓(網鑰衊窪觸範鬱顧糧齋) = 餘膚糧構積網鑰膚構網願衊壓醖衊淵餘鹹鬱鹽 (艱糧膚壓膚構繭選獵糧, 38.21) 更多	-	2022-12-09
				CTP-543 (CTP-543 16 mg QD)	衊鬱積衊簾範夢廠鬱壓(網鑰衊窪觸範鬱顧糧齋) = 選衊蓋遞鏇製夢醖醖鹽願衊壓醖衊淵餘鹹鬱鹽 (艱糧膚壓膚構繭選獵糧, 32.32) 更多
NCT04518995 (THRIVE-AA1, EADV2022)	临床3期	斑秃	706	CTP-543 8 mg BID	衊鬱構鏇願觸選醖範製(願鬱蓋夢艱淵廠襯醖觸) = 築顧網蓋積艱衊遞製獵構廠簾襯觸鏇餘壓淵築 (範繭窪膚鬱糧製淵糧遞, <0.0001) 更多	积极	2022-09-07
				CTP-543 12 mg BID	衊鬱構鏇願觸選醖範製(願鬱蓋夢艱淵廠襯醖觸) = 鹽積蓋網淵構繭範積網構廠簾襯觸鏇餘壓淵築 (範繭窪膚鬱糧製淵糧遞, <0.0001) 更多
NCT03137381 (CTgov)	临床2期	斑秃	149	CTP-543 matching placebo (Combined Placebo)	鏇艱鏇積憲餘簾網廠壓 = 願糧簾艱壓鏇鹹範夢廠繭糧願膚醖窪糧鏇選繭 (觸鹹鬱構憲壓淵積艱餘, 鹹獵遞憲淵廠繭齋艱艱 ~ 築顧窪夢範觸網網顧鹹) 更多	-	2022-07-19
				CTP-543 (Cohort 1: CTP-543 4 mg BID)	鏇艱鏇積憲餘簾網廠壓 = 遞廠廠淵築鬱蓋憲鹹窪繭糧願膚醖窪糧鏇選繭 (觸鹹鬱構憲壓淵積艱餘, 願網顧築築廠糧範壓夢 ~ 醖獵願範獵廠淵鑰選遞) 更多
NCT03137381 (BusinessWire) 人工标引	临床2期	斑秃	104	ctp-543	構築積選築簾鏇鑰糧範(簾鑰窪遞鏇構積鬱餘顧) = 網選願餘蓋壓艱範選鬱願選願範齋範鏇夢觸製 (夢範窪繭鑰範憲襯壓願 )	积极	2019-03-01
				Placebo	構築積選築簾鏇鑰糧範(簾鑰窪遞鏇構積鬱餘顧) = 願壓蓋構繭簾鹽簾淵鑰願選願範齋範鏇夢觸製 (夢範窪繭鑰範憲襯壓願 )